DSGN vs VRTX
DSGN: Design Therapeutics is a biopharmaceutical company pioneering GeneTAC small-molecule therapies to treat the root causes of serious genetic diseases. VRTX: Vertex is a leader in biotechnology primarily recognized for its dominance in cystic fibrosis therapy and its emerging pipeline of gene-editing treatments and non-opioid pain relief.
Side-by-side fundamentals
| Metric | DSGN | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $11.88 | $484.83 | |
| Market cap as of 2026-08-06 | $743M | $122.9B | |
| P/E as of 2026-08-06 | n/a | 27.95 | |
| PEG as of 2026-08-06 | -2.03 | 2.28 | DSGN lower |
| Net margin as of 2026-08-06 | -3600.0% | +35.0% | VRTX higher |
| Gross margin as of 2026-08-06 | n/a | +86.0% | |
| Operating margin as of 2026-08-06 | -3621.7% | +38.0% | VRTX higher |
| ROE as of 2026-08-06 | -33.1% | +23.3% | VRTX higher |
| ROA as of 2026-08-06 | -31.3% | +16.9% | VRTX higher |
| Debt / equity as of 2026-08-06 | 0.00 | 0.01 | DSGN lower |
| Revenue growth (YoY) as of 2026-08-06 | n/a | +10.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +10.4% | |
| Beta as of 2026-08-06 | 1.63 | 0.25 | |
| 1-year return as of 2026-07-27 close | +195.5% | +29.3% | DSGN higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.